journal article·2011-09

Surfactant-assisted controlled release of hydrophobic drugs using anionic surfactant templated mesoporous silica nanoparticles

Chih-Hsiang Tsai, Juan L. Vivero-Escoto, Igor I. Slowing, I-Ju Fang, Brian G. Trewyn, Victor S.-Y. Lin

Biomaterials· Volume 32· Issue 26
Publisher page

Abstract

A series of mesoporous silica nanoparticles (MSNs) were synthesized using the co-structure directing method. A non-cytotoxic anionic surfactant, undec-1-en-11-yltetra(ethylene glycol) phosphate monoester surfactant (PMES), was used as a structure directing agent (SDA) together with aminopropyltrimethoxysilane that functioned as a co-structure directing agent (CSDA). The morphology and mesoporous structure of these materials were tuned by changing the molar ratio of CSDA and SDA. These mesoporous nanomaterials containing PMES inside the pores showed excellent biocompatibility in vitro. The cellular internalization and endosome escape of PMES-MSNs in cervical cancer cells (HeLa) was demonstrated by flow cytometry and confocal microscopy, respectively. The PMES-MSNs were used as drug delivery carriers for resveratrol, a low water solubility drug, by taking advantage of the hydrophobic environment created by the PMES micelle inside the pores. This surfactant-assisted delivery strategy was tested under physiological conditions showing an increase of the drug loading compared to the material without surfactant and steady release of resveratrol. Finally, the therapeutic properties of resveratrol-loaded PMES-MSNs were evaluated in vitro using HeLa and Chinese hamster ovarian cells. We envision that this surfactant-assisted drug delivery method using MSNs as nanovehicles would lead to a new generation of carrier materials for intracellular delivery of a variety of hydrophobic therapeutic agents.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Mesoporous Materials and Catalysis · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (64)

Show source-provided references
1. Nanotechnology in drug delivery and tissue engineering: from discovery to applications10.1021/nl102184c ↗
2. Recent advances in intravenous delivery of poorly water-soluble compounds10.1517/17425240903307423 ↗
3. Poor aqueous solubility - an industry wide problem in drug discovery
4. Strategies in the design of nanoparticles for therapeutic applications10.1038/nrd2591 ↗
5. Recent advances with liposomes as pharmaceutical carriers10.1038/nrd1632 ↗
6. Polymer therapeutics: concepts and applications10.1002/anie.200502113 ↗
7. Dendrimers in drug research10.1039/b309043b ↗
8. Nanoparticle therapeutics: an emerging treatment modality for cancer10.1038/nrd2614 ↗
9. Porous silicon in drug delivery devices and materials10.1016/j.addr.2008.03.017 ↗
10. Gold nanoparticles in delivery applications10.1016/j.addr.2008.03.016 ↗
11. Designed fabrication of silica-based nanostructured particle systems for nanomedicine applications10.1002/adfm.200800731 ↗
12. Magnetic nanoparticles in MR imaging and drug delivery10.1016/j.addr.2008.03.018 ↗
13. Nanostructured mesoporous silica matrices in nanomedicine10.1111/j.1365-2796.2009.02190.x ↗
14. Mesostructured multifunctional nanoparticles for imaging and drug delivery10.1039/b902462j ↗
15. Mesoporous silica nanoparticles: synthesis and applications10.1142/9789814280525_0004 ↗
16. Silica nanoparticles as a delivery system for nucleic acid-based reagents10.1039/b904197d ↗
17. New developments in ordered mesoporous materials for drug delivery10.1039/b922651f ↗
18. Mesoporous silica nanoparticles for intracellular controlled drug delivery10.1002/smll.200901789 ↗
19. Mechanised nanoparticles for drug delivery10.1039/b9nr00162j ↗
20. Mesoporous silica nanoparticles: structural design and applications10.1039/c0jm00554a ↗
21. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery10.1517/17425247.2010.498816 ↗
22. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses10.1016/j.biomaterials.2009.10.046 ↗
23. The biocompatibility of mesoporous silicates10.1016/j.biomaterials.2008.07.007 ↗
24. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity10.1021/ja910846q ↗
25. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells10.1021/ja0645943 ↗
26. Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells10.1002/smll.200800926 ↗
27. Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration10.1016/j.cej.2007.09.045 ↗
28. Tuning the cellular uptake and cytotoxicity properties of oligonucleotide intercalator-functionalized mesoporous silica nanoparticles with human cervical cancer cells HeLa10.1016/j.biomaterials.2009.11.009 ↗
29. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells10.1039/b905158a ↗
30. Structure and microstructure of nanoscale mesoporous silica spheres10.1016/j.solidstatesciences.2004.01.013 ↗
31. Controlling the delivery kinetics from colloidal mesoporous silica nanoparticles with pH-sensitive gates10.1039/b918590a ↗
32. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics-the trio of imaging, targeting and therapy10.1039/c0jm00645a ↗
33. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles10.1021/ja1022267 ↗
34. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding10.1021/nn901376h ↗
35. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery10.1021/ja905793q ↗
36. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles10.1002/anie.200501819 ↗
37. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere10.1021/ja900025f ↗
38. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP10.1021/ja901831u ↗
39. A programmable DNA-based molecular valve for colloidal mesoporous silica10.1002/anie.201000827 ↗
40. Mesoporous materials for drug delivery10.1002/anie.200604488 ↗
41. Light-activated nanoimpeller-controlled drug release in cancer cells10.1002/smll.200700903 ↗
42. Nanobiohybrids as delivery vehicles for camptothecin10.1016/j.jconrel.2003.12.027 ↗
43. Encapsulation and controlled release of nutraceuticals using mesoporous silica capsules10.1039/B715100D ↗
44. Determining the cytotoxicity of catanionic surfactant mixtures on HeLa cells10.1016/j.colsurfb.2008.12.038 ↗
45. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles10.1016/j.biomaterials.2010.01.015 ↗
46. Organically functionalized mesoporous silica by co-structure-directing route10.1002/adfm.201000074 ↗
47. Synthesis of mesoporous silica materials by using anionic surfactants as template10.1627/jpi.50.299 ↗
48. A novel anionic surfactant templating route for synthesizing mesoporous silica with unique structure10.1038/nmat1022 ↗
49. Therapeutic potential of resveratrol: the in vivo evidence10.1038/nrd2060 ↗
50. Resveratrol and cellular mechanisms of cancer prevention10.1111/j.1749-6632.2010.05870.x ↗
51. Formation of self-assembled monolayers by chemisorption of derivatives of oligo(ethylene glycol) of structure HS(CH2)11(OCH2CH2)mOH on gold10.1021/ja00001a002 ↗
52. The use of fluorescence quenching in flow cytofluorometry to measure the attachment and ingestion phases in phagocytosis in peripheral blood without prior cell separation10.1016/0022-1759(87)90224-9 ↗
53. Formation of colloidal silica particles from alkoxides10.1016/0166-6622(92)80081-C ↗
54. Structure of nanoscale mesoporous silica spheres?10.1088/0953-8984/15/42/004 ↗
55. Interfacial alignment mechanism of forming spherical silica with radially oriented nanopores10.1021/jp046425f ↗
56. Anionic surfactant-templated mesoporous silica (AMS) nano-spheres with radially oriented mesopores10.1016/j.jcis.2008.04.044 ↗
57. Formation mechanism of anionic surfactant-templated mesoporous silica10.1021/cm061107+ ↗
58. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells10.1016/j.biomaterials.2007.03.006 ↗
59. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects10.1021/nn103077k ↗
60. Amino-functionalized mesoporous silica synthesized by an anionic surfactant templating route10.1039/b516863e ↗
61. High absorption but very low bioavailability of oral resveratrol in humans10.1124/dmd.104.000885 ↗
62. Bioavailability of resveratrol10.1111/j.1749-6632.2010.05842.x ↗
63. Transport, stability, and biological activity of resveratrol10.1111/j.1749-6632.2010.05871.x ↗
64. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation10.1016/S0006-291X(03)00230-4 ↗